Processing...
All Trials
Search
Search
There are 1731 active trials in our database.
Click on a trial to see more information.
1731 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with unresectable advanced/metastatic pancreatic ductal adenocarcinoma, ECOG 0–1, after progression/intolerance on exactly one prior systemic line and without prior metastatic-setting gemcitabine/nab-paclitaxel. Treatment is gemcitabine plus nab-paclitaxel with or without oral ONT01/ontegimod, an investigational CD11b/ITGAM agonist intended to reprogram tumor-associated myeloid cells.
ClinicalTrials.gov ID: NCT06904378
TrialFetch AI summary: Adults with unresectable or metastatic advanced solid tumors, particularly MSI-H/dMMR tumors, receive oral EIK1005, a Werner syndrome helicase inhibitor intended to exploit synthetic lethality in MSI-H cancers, after progression/intolerance of standard therapy or in dose-optimization cohorts. The study tests EIK1005 monotherapy and dose escalation of EIK1005 plus pembrolizumab in MSI-H/dMMR advanced solid tumors.
ClinicalTrials.gov ID: NCT07262619
TrialFetch AI summary: Enrolls men with metastatic castration-resistant prostate adenocarcinoma, generally after prior androgen receptor pathway inhibitor therapy and limited/required prior taxane exposure depending on cohort, with key exclusions including prior T-cell engager/CAR-T or radioligand therapy. All participants receive single-agent JANX014, an investigational tumor-activated PSMA × CD3 T-cell engager designed to redirect T cells against PSMA-expressing prostate cancer cells while limiting systemic T-cell activation.
ClinicalTrials.gov ID: NCT07545811
TrialFetch AI summary: Enrolls men with metastatic castration-resistant prostate cancer progressing after at least one novel androgen receptor–targeted agent, with ECOG 0–1 and no requirement for RECIST-measurable disease. All patients receive oral (R)-9bMS/mahatinib, an investigational ACK1/TNK2 tyrosine kinase inhibitor intended to suppress AR/AR-V7 signaling, in dose escalation/expansion to define safety and the recommended phase 2 dose.
ClinicalTrials.gov ID: NCT06705686
TrialFetch AI summary: Adults with radiographically metastatic castration-resistant prostate adenocarcinoma, including heavily pretreated patients in escalation/monotherapy cohorts and first-line mCRPC patients in combination expansion, receive oral INR731, an investigational agent with undisclosed target/mechanism, alone or with continued ADT plus enzalutamide or abiraterone. The study focuses on safety, dose finding, pharmacokinetics, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07570979
TrialFetch AI summary: Enrolls adults with PSMA-PET–positive mCRPC after progression on one prior ARPI, with Phase II focused on taxane-naive patients and excluding prior PSMA-targeted/radioligand therapy. Treatment evaluates oral AMO959, an investigational DNA-PK inhibitor intended to radiosensitize tumors, combined with 177Lu-PSMA-617, with or without continuous abiraterone or enzalutamide; Phase II compares AMO959 plus 177Lu-PSMA-617 plus ARPI versus 177Lu-PSMA-617 plus ARPI.
ClinicalTrials.gov ID: NCT07226986
TrialFetch AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05519293
TrialFetch AI summary: The trial involves patients who are postmenopausal women with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer, focusing on the safety and efficacy of EP0062 (vosilasarm), a selective androgen receptor modulator. Participants must have previously treated, inactive cancer and meet specific cardiac and medication criteria.
ClinicalTrials.gov ID: NCT05573126
TrialFetch AI summary: The trial investigates the use of AG01, an anti-progranulin/GP88 monoclonal antibody, in patients with relapsed or refractory advanced solid tumors, including triple negative breast cancer, hormone-resistant breast cancer, non-small cell lung cancer, and mesothelioma, who have no remaining effective treatment options. AG01 is administered biweekly to evaluate its safety, tolerability, and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05627960
TrialFetch AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.
ClinicalTrials.gov ID: NCT05227326